Even more striking, SBI-993, injected twice a week at 50 mg/kg up to 320 days, drastically reduced HCC development in response to TERT, c-myc or JARID1B overexpression, or in response to p53, axin1 or arid1a knockout (Fig. 9c, d). Here, TP53 is linked to hepatocellular carcinoma.